They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

For more on these claims, see our stories “Faulty Science Underpins Florida Surgeon General’s Call to Halt mRNA COVID-19 ...

MacMaster, Ph.D., associate professor of Microbiology-Immunology, have discovered that administering an antibody treatment ...

The UK is making progress in developing cancer vaccines, but there are still challenges ahead, Chris Baraniuk reports The UK is on its way to becoming a hotbed of cancer vaccine trials. In May this ...

mRNA technology was used to develop Moderna’s Covid-19 jab and is also being trialled to make personalised cancer vaccines as ...

Issuer: CureVac / Key word (s): Conference CureVac to Present at the 12th International mRNA Health Conference 04.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

COVID-19 vaccine DNA contamination claims aren't new, but have resurfaced in the wake of a Canadian study that some ...

the mRNA vaccine is an established platform, which Penn researchers are using to also target Lyme disease, norovirus, and a herpes virus, and are working on other targets such as cancer.